分红方面，新华保险A股上市后累计派现380.29亿元。近三年，累计派现160.03亿元。 机构持仓方面，截止2025年9月30日，新华保险十大流通股东中，香港中央结算有限公司位居第七大流 通股东，持股3644.78万股，相比上期减少2406.17万股。华泰柏瑞沪深300ETF（510300）位居第十大流 通股东，持股1431.48万股，相比上期减少58.93万股。 责任编辑：小浪快报 资料显示，新华人寿保险股份有限公司位于北京市朝阳区建国门外大街甲12号新华保险大厦，成立日期 1996年9月28日，上市日期2011年12月16日，公司主营业务涉及人寿保险业务。主营业务收入构成为： 传统型保险60.77%，分红型保险34.75%，其他业务5.09%。 新华保险所属申万行业为：非银金融-保险Ⅱ-保险Ⅲ。所属概念板块包括：高派息、H股、蚂蚁金服概 念、MSCI中国、低市盈率等。 截至9月30日，新华保险股东户数8.19万，较上期增加34.15%；人均流通股25555股，较上期减少 25.55%。2025年1月-9月，新华保险实现营业收入1372.52亿元，同比增长28.33%；归母净利润328.57亿 元，同比增长 ...

截至9月30日，中国人寿股东户数11.97万，较上期增加15.32%；人均流通股214145股，较上期减少 16.86%。2025年1月-9月，中国人寿实现营业收入0.00元；归母净利润1678.04亿元，同比增长60.54%。 分红方面，中国人寿A股上市后累计派现2263.44亿元。近三年，累计派现511.03亿元。 机构持仓方面，截止2025年9月30日，中国人寿十大流通股东中，中国证券金融股份有限公司位居第三 大流通股东，持股7.08亿股，持股数量较上期不变。华夏上证50ETF（510050）位居第五大流通股东， 持股3181.54万股，相比上期减少86.43万股。香港中央结算有限公司位居第六大流通股东，持股3001.65 万股，相比上期减少4992.24万股。华泰柏瑞沪深300ETF（510300）位居第七大流通股东，持股2837.34 万股，相比上期减少119.29万股。易方达沪深300ETF（510310）位居第八大流通股东，持股2050.28万 股，相比上期减少65.02万股。华夏沪深300ETF（510330）位居第九大流通股东，持股1529.97万股，相 比上期减少21.27万股。 12月3 ...

Core Viewpoint - China Ping An's stock performance shows a slight increase of 0.29% with a trading volume of 2.201 billion yuan and a market capitalization of 1,064.729 billion yuan [1] Dividend Analysis - The dividend yields for China Ping An over the past three years are 5.15%, 6.03%, and 4.84% respectively [2] - The top ten circulating shareholders include Central Huijin Asset Management Co., Ltd. and China Securities Finance Corporation [2] - The company owns Fintech subsidiary OneConnect, providing electronic banking, account services, credit reporting, loans, and interbank transactions to small and medium-sized banks [2] - China Ping An has stakes in several unicorn companies, including Lufax, Ping An Good Doctor, and a health insurance company, with Lufax valued at 39.4 billion USD as of March 2019 [2] Fund Flow Analysis - Today's main capital net inflow is -22.6088 million yuan, accounting for 0.01%, with the industry ranking at 3 out of 5, indicating a reduction in main capital positions for two consecutive days [3] - Over the past 20 days, the main capital net inflow totals -1.035 billion yuan, showing a trend of capital reduction [4] Technical Analysis - The average trading cost of the stock is 52.62 yuan, with recent accumulation activity noted, although the strength of accumulation is weak [5] - The current stock price is near a support level of 58.40 yuan, and a drop below this level may trigger a downward trend [5] Company Overview - China Ping An Insurance (Group) Co., Ltd. is headquartered in Shenzhen, Guangdong, and was established on March 21, 1988, with its listing date on March 1, 2007 [6] - The company offers diversified financial services centered around insurance, including banking, securities, and trust services, with revenue composition as follows: life and health insurance 45.76%, property insurance 34.46%, banking 13.87%, asset management 5.27%, and financial empowerment 3.85% [6] - As of September 30, 2025, the number of shareholders is 696,200, a decrease of 3.43% from the previous period, with an average of 15,401 circulating shares per person [6] - For the period from January to September 2025, the company reported a net profit of 132.856 billion yuan, a year-on-year increase of 11.47% [6] Dividend Distribution - Since its A-share listing, China Ping An has distributed a total of 391.904 billion yuan in dividends, with 134.54 billion yuan distributed over the past three years [7] - As of September 30, 2025, Hong Kong Central Clearing Limited is the sixth-largest circulating shareholder, holding 456 million shares, a decrease of 182 million shares from the previous period [7]

Core Viewpoint - Xinhua Insurance's stock price has shown a significant increase of 43.28% year-to-date, despite a slight decline in recent trading days, indicating a volatile but generally positive market sentiment towards the company [1][2]. Financial Performance - As of September 30, 2025, Xinhua Insurance reported a net profit of 32.857 billion yuan, reflecting a year-on-year growth of 58.88% [2]. - The company has cumulatively distributed dividends amounting to 35.939 billion yuan since its A-share listing, with 13.913 billion yuan distributed over the past three years [3]. Shareholder Information - The number of shareholders for Xinhua Insurance reached 81,900, an increase of 34.15% compared to the previous period, while the average number of circulating shares per person decreased by 25.55% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 36.4478 million shares, a decrease of 24.0617 million shares from the previous period [3]. Stock Market Activity - On November 19, Xinhua Insurance's stock price rose by 2.03%, reaching 68.36 yuan per share, with a total market capitalization of 213.252 billion yuan [1]. - The trading volume indicated a net inflow of 671,900 yuan from main funds, with significant buying and selling activity observed [1].

Core Viewpoint - Xinhua Insurance's stock price has experienced fluctuations, with a year-to-date increase of 40.12% but a recent decline in the last five trading days by 2.58% [1] Financial Performance - As of September 30, 2025, Xinhua Insurance reported a net profit of 32.857 billion yuan, representing a year-on-year growth of 58.88% [2] - The company achieved zero operating revenue for the period from January to September 2025 [2] Shareholder Information - The number of shareholders increased by 34.15% to 81,900 as of September 30, 2025, while the average number of circulating shares per person decreased by 25.55% to 25,555 shares [2] - Cumulative cash dividends since the A-share listing amount to 35.939 billion yuan, with 13.913 billion yuan distributed over the last three years [3] Stock Market Activity - On November 17, Xinhua Insurance's stock price was 66.85 yuan per share, with a market capitalization of 208.542 billion yuan [1] - The stock experienced a net outflow of 77.612 million yuan in principal funds, with significant selling pressure observed [1] Business Composition - The main business revenue composition includes traditional insurance at 60.77%, participating insurance at 34.75%, and other businesses at 5.09% [1]

Core Viewpoint - China Life Insurance's stock price has experienced fluctuations, with a recent decline of 2.02%, while the company shows a year-to-date increase of 4.89% in stock price [1][2]. Group 1: Stock Performance - As of November 17, China Life's stock price is 43.25 CNY per share, with a market capitalization of 1,222.448 billion CNY [1]. - The stock has seen a 2.70% decline over the past five trading days, a 1.76% increase over the past 20 days, and a 2.78% increase over the past 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, China Life reported a net profit of 167.804 billion CNY, marking a year-on-year growth of 60.54% [2]. - The company has distributed a total of 226.344 billion CNY in dividends since its A-share listing, with 51.103 billion CNY distributed over the last three years [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders has increased to 119,700, a rise of 15.32% from the previous period [2]. - The average number of circulating shares per shareholder is 214,145, which is a decrease of 16.86% compared to the previous period [2].

Group 1 - China Pacific Insurance's subsidiary, China Pacific Life, reported a cumulative premium income of 241.32 billion yuan for the first ten months, a year-on-year increase of 9.9% [1] - China Pacific Property Insurance, another subsidiary, achieved a cumulative premium income of 173.57 billion yuan, with a year-on-year growth of 0.4% [1] - Nocera Biopharma reported a net loss of 64.41 million yuan for the first three quarters, despite a revenue increase of 59.85% to 1.115 billion yuan [1] Group 2 - Founder Securities received approval from the China Securities Regulatory Commission to issue short-term corporate bonds not exceeding 5 billion yuan [1] - Haicheng Bonda's director plans to reduce his stake by up to 0.97%, equating to 198,400 shares [1] - Yuyuan Group intends to repurchase shares worth between 200 million and 300 million yuan, with a maximum price of 8.60 yuan per share [1] Group 3 - Huaren Shuanghe's subsidiary passed the GMP compliance inspection for a specific diabetes medication [4] - Lichong Group received project notifications from three international automotive manufacturers, with expected sales amounting to approximately 1.135 billion yuan [6] - Deyang Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [7] Group 4 - Longxin General announced the transfer of its entire stake in a subsidiary for 105.6 million yuan, and also plans to divest another stake for 1 yuan due to poor performance [16] - Kangda New Materials decided to terminate the acquisition of a semiconductor company due to unsatisfactory due diligence progress [17] - Lu'an Environmental reported a 3.28% year-on-year increase in coal sales for October, totaling 3.78 million tons [18] Group 5 - Shanghai Port Group plans to invest 2 billion yuan to establish a new holding company with several state-owned enterprises [20] - Borui Pharmaceutical's new drug for obesity treatment has received clinical trial approval [23] - Silver Dragon Co. has completed the registration of a new energy industry fund focusing on high-growth potential projects [24] Group 6 - Hengrui Medicine received approval for a clinical trial of a prostate cancer drug [11] - Baiji Shenzhou reported a net profit of 1.139 billion yuan for the first three quarters, marking a turnaround from losses [36] - Huasheng Pharmaceutical's special medical food product has received registration certification [60]

Group 1 - Longjian Co., Ltd. won a bid for a highway maintenance project in Heilongjiang with a contract value of 483 million yuan, accounting for 2.64% of the company's expected revenue for 2024 [1] - Transsion Holdings plans to issue H-shares and list on the main board of the Hong Kong Stock Exchange [1] - Good Home's controlling shareholder intends to reduce its stake by up to 2.7%, equivalent to no more than 39.4468 million shares [1][2] Group 2 - Xinhua Insurance reported a cumulative premium income of 181.973 billion yuan from January to October, representing a year-on-year growth of 17% [2][4] - Zhejiang Jiaokao is part of a consortium that plans to bid for a new urbanization project with an estimated total investment of 11.103 billion yuan [4] Group 3 - Changchun High-tech received approval for clinical trials of a vaccine for adolescents and adults [6] - XinNuoWei's application for the listing of Pertuzumab injection has been accepted, targeting HER2-positive breast cancer [8] - Dash Smart won a bid for an intelligent project at the new Huanggang Port inspection building, valued at 55.056 million yuan, which is 1.74% of its expected revenue for 2024 [8] Group 4 - Electronic City is involved in a lawsuit for debt recovery, with the amount in dispute estimated at 777 million yuan [9] - Haibo Technology signed a strategic cooperation agreement with CATL for a cumulative procurement of no less than 200 GWh of electricity from 2026 to 2028 [10] Group 5 - Renfu Pharmaceutical's HW231019 tablets have entered the second phase of clinical trials for postoperative pain relief [11] - Tonghua Dongbao received a drug registration certificate for Aspart Insulin injection from the Dominican Republic [11] Group 6 - Shaanxi Construction reported winning major projects worth a total of 1.016 billion yuan in October [12] - Fuzhou Environmental Protection plans to change its stock name to "Fuzhou Technology" [12] Group 7 - Panlong Pharmaceutical's gel patch for knee osteoarthritis has received approval for clinical trials [15] - Zhongyida's application for a specific stock issuance has been terminated by the Shanghai Stock Exchange [16] Group 8 - Zhizhong Home's controlling shareholder reduced its holdings of convertible bonds by 905,000 units, accounting for 13.51% of the total issued [19] - Haibo Co., Ltd. plans to establish a subsidiary with an investment of 1 billion yuan for high-end component projects [21] Group 9 - Caina Co. plans to use 57 million yuan of idle funds to purchase structured deposits [23] - Zhendong Pharmaceutical's new drug for acute ischemic stroke has entered the IIa phase of clinical trials [25] Group 10 - Weiman Sealing's overseas subsidiary plans to lease a factory in Saudi Arabia for 5 years at a total rent of approximately 54.039 million yuan [26] - Yiling Pharmaceutical's application for Memantine Hydrochloride has been approved for market entry [28] Group 11 - Dongfang Zhizao plans to acquire 70% of Saifu Machinery for 27.4887 million yuan [30] - JianKai Technology's actual controller intends to transfer 3% of the company's shares through inquiry [31] Group 12 - Rejing Bio plans to repurchase shares worth between 100 million and 200 million yuan [32] - Bangji Technology has decided to terminate a major asset restructuring project due to failure to reach an agreement [34] Group 13 - Huadong Pharmaceutical's application for the marketing license of a new drug has been accepted [36] - Zhonggu Logistics' shareholder plans to reduce its stake by up to 3% [38] Group 14 - Bohui Innovation's subsidiary received approval for a clinical trial of a vaccine for invasive infections [40] - Shannon Chip's shareholder pledged 0.27% of the company's shares for financing [42] Group 15 - Shanghai Petrochemical appointed a new general manager [44] - Jiaojian Co. plans to reduce the holdings of some directors and executives by up to 0.35% [46] Group 16 - Weiting Electric plans to raise no more than 300 million yuan through a private placement [47] - Zhongjin Irradiation plans to invest approximately 200 million yuan in an electronic accelerator manufacturing project [49] Group 17 - Tongxing Technology signed a framework agreement to invest 3.2 billion yuan in a sodium battery project [50] - Hongri Da plans to establish a subsidiary focused on semiconductor packaging [51] Group 18 - Shanghai Kaibao's new drug for acute ischemic stroke has received approval for clinical trials [53] - Yitong Century announced a change in its control structure, becoming a company without a controlling shareholder [55]

Core Viewpoint - China Life Insurance's stock price has shown a positive trend, with significant increases in both share price and net profit, indicating strong financial performance and investor interest [1][2]. Group 1: Stock Performance - As of November 12, China Life's stock price increased by 2.04%, reaching 44.62 CNY per share, with a total market capitalization of 1,261.17 billion CNY [1]. - Year-to-date, the stock price has risen by 8.22%, with a 3.62% increase over the last five trading days, 10.28% over the last 20 days, and 10.33% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, China Life reported a net profit of 167.80 billion CNY, representing a year-on-year growth of 60.54% [2]. - The company has distributed a total of 226.34 billion CNY in dividends since its A-share listing, with 51.10 billion CNY distributed over the last three years [2]. Group 3: Shareholder Structure - As of September 30, 2025, the number of shareholders increased to 119,700, a rise of 15.32% from the previous period [2]. - The top shareholder, China Securities Finance Corporation, holds 708 million shares, while other major shareholders have seen reductions in their holdings [2].

Core Viewpoint - Xinhua Insurance's stock price has shown a significant increase of 40.93% year-to-date, despite a recent decline of 2.01% on November 11, with a current trading price of 67.24 CNY per share [1]. Financial Performance - For the period from January to September 2025, Xinhua Insurance reported a net profit of 32.857 billion CNY, marking a year-on-year growth of 58.88% [2]. - The company has cumulatively distributed dividends of 35.939 billion CNY since its A-share listing, with 13.913 billion CNY distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders increased by 34.15% to 81,900, while the average number of circulating shares per person decreased by 25.55% to 25,555 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 36.448 million shares, a decrease of 24.0617 million shares from the previous period [3]. Market Activity - On November 11, the trading volume reached 596 million CNY, with a turnover rate of 0.42% and a total market capitalization of 209.758 billion CNY [1]. - The net outflow of main funds was 10.4001 million CNY, with large orders accounting for 32.65% of purchases and 31.75% of sales [1].